Given elevated alkaline phosphatase, impaired renal function (estimated glomerular filtration rate ≈35 mL/min/1.73 m²), hyperkalaemia, elevated blood urea nitrogen and creatinine, anemia with low red blood cell count, low hemoglobin, low hematocrit, low mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration, and elevated red cell distribution width, what is the likely diagnosis and how should it be treated?

Chronic Kidney Disease with Anemia and Severe Hyperkalemia

You have chronic kidney disease (CKD) Stage 3b with anemia of CKD and severe hyperkalemia requiring immediate attention to prevent life-threatening cardiac arrhythmias.

Primary Diagnoses

Your laboratory values indicate three critical conditions:

1. Chronic Kidney Disease (Stage 3b)

• GFR 35 mL/min/1.73 m² places you in CKD Stage 3b 1
• Elevated BUN (34) and creatinine (1.46) confirm impaired kidney function
• Elevated alkaline phosphatase (192) may reflect mineral-bone disease complications of CKD 2, 3

2. Anemia of Chronic Kidney Disease

• Hemoglobin 8.7 g/dL is significantly below normal (normal: men >13 g/dL, women >12 g/dL) 4
• RBC 3.47, hematocrit 30.8% are proportionally low
• Low MCH (25.1) and MCHC (28.2) suggest hypochromic anemia, likely iron deficiency
• Elevated RDW (20.9) indicates significant red cell size variation, associated with worse kidney function and mortality 5
• Anemia prevalence at your GFR level (30-40 mL/min) is approximately 22-40% 6

3. Severe Hyperkalemia

• Potassium 6.0 mEq/L meets criteria for severe hyperkalemia (>6.0 mEq/L) 7
• This is life-threatening and requires urgent intervention
• At your GFR level, hyperkalemia prevalence is approximately 8% 8, 9

Immediate Treatment for Hyperkalemia

Your potassium level of 6.0 requires urgent treatment to prevent cardiac arrest 7:

Acute Management (First 24-48 hours):

1. Obtain ECG immediately to assess for cardiac toxicity (peaked T-waves, widened QRS)

2. If ECG changes present:

   • IV calcium gluconate 10% (10 mL over 2-3 minutes) for cardiac membrane stabilization
   • IV insulin (10 units regular) with dextrose (25g) to shift potassium intracellularly
   • Consider sodium bicarbonate if acidotic
   • Inhaled albuterol (10-20 mg nebulized)

3. Potassium removal:

   • Oral sodium polystyrene sulfonate (Kayexalate) 15-30g, OR
   • Newer potassium binders (preferred): patiromer or sodium zirconium cyclosilicate 10
   • Loop diuretics if not volume depleted

Chronic Management:

1. Dietary potassium restriction to <2,000-3,000 mg/day 11

   • Avoid bananas, oranges, potatoes, tomatoes, legumes, chocolate
   • Limit salt substitutes (contain potassium)

2. Review and adjust medications 7:

   • Stop or reduce ACE inhibitors, ARBs, spironolactone, NSAIDs, trimethoprim if taking
   • These medications commonly cause hyperkalemia in CKD

3. Consider loop diuretics (protective against hyperkalemia) 9

4. Monitor potassium weekly until stable <5.0 mEq/L, then monthly

Treatment for Anemia of CKD

Your hemoglobin of 8.7 g/dL requires investigation and treatment 4:

Diagnostic Workup:

1. Iron studies immediately:

   • Serum iron, transferrin saturation, ferritin
   • Target transferrin saturation ≥30% regardless of ferritin 10
   • Vitamin B12 and folate levels

2. Check for blood loss sources (especially GI bleeding)

Treatment:

1. Iron replacement:

   • IV iron preferred over oral in CKD (better absorption and response) 10
   • Oral iron if IV not available: ferrous sulfate 325mg daily

2. Erythropoiesis-stimulating agents (ESAs):

   • Consider if hemoglobin remains <10 g/dL after iron repletion
   • Target hemoglobin 10-11.5 g/dL (not higher due to cardiovascular risks)

3. Replace vitamin deficiencies if identified

Management of CKD Stage 3b

Dietary Modifications:

1. Protein restriction to 0.8 g/kg/day 12
2. Phosphorus restriction to 800-1,000 mg/day 12
3. Sodium restriction to <2g/day 10
4. Potassium restriction <2,000-3,000 mg/day 11

Medications to Consider:

1. SGLT2 inhibitor (if diabetic or have proteinuria) - reduces CKD progression 13
2. ACE inhibitor or ARB - BUT ONLY after potassium controlled <5.0 mEq/L 13
3. Phosphate binders if phosphorus elevated
4. Vitamin D supplementation - target 25(OH)D >30 ng/dL 10

Monitoring:

1. Monthly initially:

   • Potassium, creatinine, BUN
   • Hemoglobin, iron studies
   • Calcium, phosphorus, PTH

2. Every 3-4 months once stable:

   • Complete metabolic panel
   • CBC
   • Mineral metabolism parameters

Nephrology Referral:

You need nephrology referral now 10:

• CKD Stage 3b with complications (anemia, hyperkalemia)
• Allows planning for potential dialysis or transplantation
• Expert management of mineral-bone disease

Critical Pitfalls to Avoid

1. Do NOT continue potassium-sparing medications (spironolactone, amiloride, triamterene) with K+ 6.0 7
2. Do NOT use potassium-containing salt substitutes
3. Do NOT delay ECG with severe hyperkalemia - cardiac arrest can occur suddenly 7
4. Do NOT target hemoglobin >11.5 g/dL with ESAs (increases cardiovascular events)
5. Do NOT ignore elevated alkaline phosphatase - may indicate mineral-bone disease requiring specific treatment 2, 3

Prognosis

Your elevated RDW (20.9) and alkaline phosphatase (192) are independent predictors of mortality in CKD 5, 3, 14. Aggressive management of hyperkalemia, anemia, and CKD progression is essential to improve outcomes. The combination of severe hyperkalemia and anemia significantly increases hospitalization and mortality risk if left untreated 7.